Tandem Diabetes Care (TNDM) Amortization of Deferred Charges (2013 - 2026)
Tandem Diabetes Care (TNDM) posted Amortization of Deferred Charges of $576000.0 for Q1 2026, up 29.15% on a QoQ basis from $446000.0 in Q4 2025, and up 14.06% year-over-year from $505000.0 in Q1 2025.
Tandem Diabetes Care (TNDM) Amortization of Deferred Charges (2013 - 2026) Analysis & Trends
Tandem Diabetes Care's Amortization of Deferred Charges history runs 13 years deep, the most recent figure standing at $576000.0 for Q1 2026.
- Quarterly Amortization of Deferred Charges rose 14.06% year-over-year to $576000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 0.67% YoY) and the FY2025 annual result came in at $1.9 million, down 10.96% from the prior year.
- Amortization of Deferred Charges was $576000.0 for Q1 2026 at Tandem Diabetes Care, up from $446000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $702000.0 in Q3 2023 and bottomed at $435000.0 in Q2 2024.
- A 5-year average of $504000.0 and a median of $498000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2023 — Amortization of Deferred Charges soared 40.96% — and 2024, when it fell 28.49%.
- Tandem Diabetes Care's Amortization of Deferred Charges stood at $501000.0 in 2022, then slipped by 1.6% to $493000.0 in 2023, then climbed by 1.83% to $502000.0 in 2024, then declined by 11.16% to $446000.0 in 2025, then increased by 29.15% to $576000.0 in 2026.
- Business Quant data shows TNDM's Amortization of Deferred Charges at $576000.0 in Q1 2026, $446000.0 in Q4 2025, and $444000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.73 Bn | 176.43 Bn | 6.27 Bn |
| 2 | Stryker | 129.05 Bn | 126.17 Bn | 3.81 Bn |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.63 Bn | 67.18 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.43 Bn | 44.76 Bn | 1.29 Bn |
| 6 | Dexcom | 28.36 Bn | 27.24 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.14 Bn | 25.85 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.89 Bn | 26.32 Bn | - |
| 9 | Koninklijke Philips | 24.25 Bn | 21.12 Bn | 2.07 Bn |
| 10 | Tandem Diabetes Care | 1.14 Bn | 567.87 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 576,000.00 |
| Mar 31, 2026 | 576,000.00 |
| Dec 31, 2025 | 446,000.00 |
| Dec 31, 2025 | 446,000.00 |
| Sep 30, 2025 | 444,000.00 |
| Sep 30, 2025 | 444,000.00 |
| Jun 30, 2025 | 465,000.00 |
| Jun 30, 2025 | 465,000.00 |
| Mar 31, 2025 | 505,000.00 |
| Mar 31, 2025 | 505,000.00 |
| Dec 31, 2024 | 502,000.00 |
| Dec 31, 2024 | 502,000.00 |
| Sep 30, 2024 | 502,000.00 |
| Sep 30, 2024 | 502,000.00 |
| Jun 30, 2024 | 435,000.00 |
| Jun 30, 2024 | 435,000.00 |
| Mar 31, 2024 | 650,000.00 |
| Mar 31, 2024 | 650,000.00 |
| Dec 31, 2023 | 493,000.00 |
| Dec 31, 2023 | 493,000.00 |